RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
 - EconoTimes)
NEW ORLEANS, Jan. 27, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 27, 2017 to file lead plaintiff applications in a securities class action lawsuit against PixarBio Corporation (Other OTC:PXRB), if they purchased the Company’s securities pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016 and/or between October 31, 2016 and January 20, 2017, inclusive (the “Class Period”). The action is pending in United States District Court for the District of New Jersey.
What You May Do
If you purchased securities of PixarBio and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 27, 2017.
About the Lawsuit
PixarBio and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the market for PixarBio’s securities exhibited manipulative or deceptive activities; and (ii) PixarBio’s assertions in press releases, third-party promotional materials, and PixarBio’s Form S-1 concerning, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees and PixarBio’s current and prospective development efforts were untrue.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
